Scintipharma
Lexington, Kentucky, United States
NCT Number: NCT01698060
The purpose of the study is to determine the safety and tolerability of ND1.1, an adjuvanted adenoviral-based avian influenza vaccine, when delivery is targeted to the ileum, using a radio controlled capsule. The secondary objective is to evaluate the immune response (cellular and humoral) of two doses of ND1.1 oral vaccine.
Looking for future studies?
Notify Me18 year–49 year
Male
Interventional
Phase 1
Lexington, Kentucky, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 1 year
Frequency and magnitude of adverse events
Time frame: 1 year
Antibody and T cell responses to HA
Vaxart
Industry
An Open Label Phase I Substudy to Evaluate the Safety and Ability to Enhance Immunogenicity of ND1.1 by Delivery Directly to the Ileum Using the InteliSite® Companion Capsule in Healthy Adult Males
Acronym: ICC H5
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07019883
Animal Diseases, Avian Influenza
Durham, North Carolina, United States
View Trial DetailsNCT02839330
Animal Diseases, Avian Influenza
Huntsville, Alabama, United States
View Trial DetailsNCT02921997
Animal Diseases, Avian Influenza
Nashville, Tennessee, United States
View Trial DetailsNCT03014310
Animal Diseases, Avian Influenza
Atlanta, Georgia, United States
View Trial Details